Skip to main content
. 2014 Nov 16;6(1):85–100. doi: 10.18632/oncotarget.2765

Fig.3. WMJ-S-001 inhibited VEGFR2 signaling pathways in HUVECs.

Fig.3

Cells were pretreated with indicated concentrations of WMJ-S-001 for 30 min, followed by the addition with VEGF-A (20 ng/ml) for another 5 (VEGFR2) or 20 (Src, FAK, Akt and ERK1/2) min. Phosphorylation status of VEGFR2 (A), Src (B), FAK (C), Akt (D), and ERK1/2 (E) were then determined by immunoblotting. The compiled results of VEGFR2 Tyr1175 and Tyr1214 (A), Src Tyr416 (B), FAK Tyr397 (C), Akt Ser473 (D), and ERK1/2 Thr202/Tyr204 (E) phosphorylations are shown. Each column represents the mean ± S.E.M. of at least four independent experiments. *p < 0.05, compared with the control group; #p < 0.05, compared with the group treated with VEGF-A alone.